Company Interview / The small cap using data to drive results

Key points:

- Pathkey.AI’s TrialKey platform analyses 500,000 clinical trials, using 1,500 data points per trial

- TrialKey assists in predicting clinical trial success and helps optimise trial design

- Small-to-medium biotechs and listed companies benefit most, with impact observed on share prices

- Positive response from biotech sector, with TrialKey promoting competition against big pharma

Damon Rasheed from Pathkey.AI highlights how the company’s advanced AI platform, TrialKey, is transforming the way biotech and pharmaceutical companies approach clinical trial success. Rasheed states that the industry historically lacks data-driven tools to predict trial outcomes, despite the high cost—often $30-40 million per phase. Pathkey.AI has developed a proprietary dataset containing over 500,000 clinical trials, covering 1,500 features per trial, collected from the past 25 years. By leveraging this vast database, the TrialKey model aims to not only forecast success rates but also help design more efficient and effective clinical trials.

Rasheed says TrialKey is particularly valuable for investors and for small-to-medium biotechs, where accurate prediction of clinical trial results can significantly affect share prices. He observes that the model’s predictive capability is validated both statistically and through real-world share price movements following inflection events observed at listed companies. Testing on 20,000 unseen inflection points shows highly accurate results, suggesting the model can reveal market opportunities not fully captured by traditional research.

Feedback from biotech management in Australia and the US is described as overwhelmingly positive, with many companies previously unaware of quantifiable success probabilities. Rasheed notes that TrialKey is now bridging the gap for early-stage biotechs, universities, and hospitals in competition with larger pharmaceutical firms.